Meeting
2024 ASCO Genitourinary Cancers Symposium
Safety and clinical validity of tumor genomic testing for guiding active surveillance selection in men with NCCN intermediate-risk prostate cancer.
Authors
Lauren Lenz
Myriad Genetics, Inc., Salt Lake City, UT
Lauren Lenz , Wyatt Clegg , Diana Iliev , Howard Korman , Todd Matthew Morgan , Jason Hafron , Alexander DeHaan , Ronald F. Tutrone , Timothy Richardson , Kevin Cline , Paul M. Yonover , Jeff Jasper , Alexander Gutin , Robert Finch , Thomas Paul Slavin Jr., Todd Cohen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 336)
DOI
10.1200/JCO.2024.42.4_suppl.336
Abstract #
336
Poster Bd #
P5
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Adverse pathology as a predictor of distant metastasis and prostate cancer mortality with 20-year follow up.
First Author: Michael Austin Brooks
Poster
2021 Genitourinary Cancers Symposium
PSA velocity to predict clinical progression in African American and non-Hispanic White patients with low-risk prostate cancer undergoing active surveillance.
First Author: Juan Javier-Desloges
Poster
2020 Genitourinary Cancers Symposium
Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer.
First Author: Jonathan David Tward
Poster
2019 Genitourinary Cancers Symposium
Outcomes of active surveillance for African-American men with prostate cancer: Results of a matched analysis.
First Author: Lewis Thomas